Neuro-immuno-endocrine processes in vitiligo pathogenesis

International Journal of Immunopathology and Pharmacology

Volumn 25, Issue 1, 2012, Pages 1-7

  Miniati, A ^a,c   Weng, Z ^a,b   Zhang, B ^a,b   Stratigos, A J ^c   Nicolaidou, E ^c   Theoharides, T C ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY   (United States)

^c ANDREAS SYGROS HOSPITAL   (Greece)

Author keywords

Autoimmunity; Corticotropin releasing hormone (CRH); Inflammation; Mast cells; Thymic stromal lymphopoietin (TSLP); Vitiligo

Indexed keywords

ALPHA INTERMEDIN; AMINE OXIDASE (FLAVIN CONTAINING); CATALASE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; GAMMA INTERFERON; GLUTATHIONE PEROXIDASE; GLYCOPROTEIN GP 100; HEAT SHOCK PROTEIN 70; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 33; INTERLEUKIN 6; INTERLEUKIN 9; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELAN A; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; NEUROPEPTIDE; NEUROTENSIN; PHENYLALANINE 4 MONOOXYGENASE; PROOPIOMELANOCORTIN; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; STEM CELL FACTOR; THYMIC STROMAL LYMPHOPOIETIN; TUMOR NECROSIS FACTOR; TYROSINASE RELATED PROTEIN 1; VASCULOTROPIN;

ALOPECIA AREATA; ANGIOGENESIS; APOPTOSIS; ATOPIC DERMATITIS; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; BLOOD VESSEL PERMEABILITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DAMAGE; CELL DEATH; CELL FUNCTION; CELL VIABILITY; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; DNA POLYMORPHISM; ENZYME INHIBITION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC PREDISPOSITION; HASHIMOTO DISEASE; HOMEOSTASIS; HUMAN; HUMORAL IMMUNITY; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN DEPENDENT DIABETES MELLITUS; MAST CELL; MELANOCYTE; MELANOGENESIS; NERVE ENDING; ONSET AGE; OXIDATIVE STRESS; PRIORITY JOURNAL; PSORIASIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; URTICARIA; VITILIGO; ENDOCRINE CELL; NEUROCHEMISTRY; NEUROIMMUNOLOGY; PATHOGENESIS;

EID: 84861466282     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201202500101     Document Type: Review

References (48)

1. Tobin DJ, Nelle N. Swanson, Mark R. Pittelkow, Peters EM, Schallreuter KU: Melanocytes are not absent in lesional skin of long duration vitiligo. J Pathol 2000; 191 (4):407-16. (Pubitemid 30649910)
2. Schallreuter KU, Bahadoran P, Picardo M, et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol 2008; 17(2): 139-40.
3. Spritz RA. The genetics of generalized vitiligo: autoimmune pathways and an inverse relationship with malignant melanoma. Genome Med 2010; 2(10):78.
4. Jin Y, Birlea SA, Fain PR, et al. Genome-wide analysis identifies a quantitative trait locus in the MHC class II region associated with generalized vitiligo age of onset. J Invest Dermatol 2011; 131(6):1308-12.
5. Cheong KA, Chae SC, Kim YS, Kwon HB, Chung HT, Lee AY. Association of thymic stromal lymphopoietin gene -847C>T polymorphism in generalized vitiligo. Exp Dermatol 2009; 18(12):1073-5.
6. Birlea SA, Jin Y, Bennnett DC, et al. Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3 and TSLP. J Invest Dermatol 2011; 131:371-81.
7. Ziegler SF, Artis D. Sensing the outside world: TSLP regulates barrier immunity. Nat Immunol 2010; 11(4):289-93.
8. Spritz RA. The genetics of generalized vitiligo and associated autoimmune diseases. J Dermatol Sci 2006;41(1):3-10. (Pubitemid 43075427)
9. Wańkowicz-Kalińska A, van den Wijngaard RM, Tigges BJ, Westerhof W, Ogg GS, Cerundolo V, Storkus WJ, Das PK. Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest 2003; 83(5):683-95. (Pubitemid 36618047)
10. Aroni K, Voudouris S, Ioannidis E, Grapsa A, Kavantzas N, Patsouris E. Increased angiogenesis and mast cells in the center compared to the periphery of vitiligo lesions. Arch Dermatol Res 2010; 302: 601-7.
11. Mandelcorn-Monson RL, Shear NH, Yay E, et al. Cytotoxic T lymphocyte reactivity to gp 100, MelanA/MART1 and tyrosinase in HLA-A2-positive vitiligo patients. J Invest Dermatol 2003; 121:550-6. (Pubitemid 37072267)
12. van Geel N, Speeckaert R, Taieb A, et al.: on behalf of the other VETF members. Koebner's phenomenon in vitiligo: European position paper. Pigment Cell Melanoma Res 2011; 24(3):564-73.
13. Sandoval-Cruz M, García-Carrasco M, Sánchez-Porras R, Mendoza-Pinto C, Jiménez-Hernández M, Munguía-Realpozo P, Ruiz-Argüelles A. Immunopathogenesis of vitiligo. Autoimmun Rev 2011; 10(12):762-5.
14. Song YH. Why tyrosinase for treatment of melanoma? Lancet 1997; 350:82-3.
15. Waterman EA, Gawkrodger DJ, Watson PF, Weetman AP, Kemp EH. Autoantigens in vitiligo identified by the serological selection of a phage-displayed melanocyte cDNA expression library. J Invest Dermatol 2010; 130(1):230-40.
16. Kemp EH, Emhemad S, Akhtar S, Watson PF, Gawkrodger DJ, Weetman AP. Autoantibodies against tyrosinase hydroxylase in patients with non-segmental (generalized) vitiligo. Exp Dermatol 2011; 20(1):35-40.
17. Guerra L, Dellambra E, Brescia S, Raskovic D. Vitiligo: Pathogenetic hypotheses and targets of current therapies. Curr Drug Metab 2010; 11(5):451-67.
18. Salem MM, Shalbaf M, Gibbons NC, Chavan B, Thornton JM, Schallreuter KU. Enhanced DNA binding capacity on up-regulated epidermal wild-type p53 in vitiligo by H2O2-mediated oxidation: a possible repair mechanism for DNA damage. FASEB 2009; 23(11):3790-807.
19. Moretti S, Fabbri P, Baroni G, Berti S, Bani D, Berti E, Nassini R, Lotti T, Massi D. Keratinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis. Histol Histopathol 2009; 24(7):849-57.
20. Kirnbauer R, Charvat B, Schauer E, et al. Modulation of intercellular adhesion molecule-1 expression on human melanocytes and melanoma cells: evidence for a regulatory role of IL-6, IL-7, TNF beta, and UVB light. J Invest Dermatol 1992; 98(3):320-6.
21. Al'Abadie MS, Senior HJ, Bleehen SS, Gawkradger DJ. Neuropeptides and neuronal marker studies in vitiligo. Br J Dermatol 1994; 131(2):160-5. (Pubitemid 24251486)
22. Manolache L, Petrescu-Seceleanu D, Benea V. Correlation of stressful events with onset of vitiligo in children. J Eur Acad Dermatol Venereol 2009; 23(2):187-8.
23. Kumar R, Parsad D, Kanwar AJ. Role of apoptosis and melanocytorrhagy: a comparative study of melanocyte adhesion in stable and unstable vitiligo. Br J Dermatol 2011; 164(1):187-91.
24. McGill GG, Horstmann M, Widlund HR, et al. Bcl-2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 2002; 109:707-18. (Pubitemid 34722267)
25. Kitamura Y, Morii E, Jippo T, Ito A. Regulation of mast cell phenotype by MITF. Int Arch Allergy Immunol 2002; 127(2):106-9. (Pubitemid 34264195)
26. Sonnenblick A, Levy C, Razin E. Interplay between MITF, PIAS3 and STAT3 in mast cells and melanocytes. Mol Cel Biol 2004; 24(24):10584-92. (Pubitemid 39603118)
27. Noelle RJ, Nowak EC. Cellular sources and immune functions of interleukin-9. Nat Rev Immunol 2010; 10(10):683-7.
28. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Immunol 2010; 10:103-10.
29. Ziegler SF. The role of thymic stromal lymphopoietin (TSLP) in allergic disorders. Curr Op Immunol 2010; 22:795-99.
30. Berti S, Amato L, Arunachalam M, Spallanzani A, Prignano F, Nassini R, Massi D, Colucci R, Moretti S. Mast cells do not play a role in vitiligo. Eur J Dermatol 2011; 21(5):800-1.
31. Theoharides TC, Zhang B, Kempuraj D, et al. IL-33 augments substance P-induced VEGF release from human mast cells arid is increased in psoriatic skin. Proc Natl Acad Sci USA 2010; 107(9):4448-53.
32. Zhang B, Alysandratos KD, Angelidou A, et al. Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: Relevance to atopic dermatitis. J Allergy Clin Immunol 2011; 127(6):1522-31.
33. Kim NH, Torchia D, Rouhani P, Roberts B, Romanelli P. Tumor necrosis factor-α in vitiligo: direct correlation between tissue levels and clinical parameters. Cutan Ocul Toxicol 2011; 30(3):225-7.
34. Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci 2004; 25(11):563-8. (Pubitemid 39371146)
35. Slominski A, Wortsman J, Tuckey RC, Paus R. Differential expression of HPA axis homolog in the skin. Mol Cell Endocrinol 2007; 265-266:143-9. (Pubitemid 46273958)
36. Zbytek B, Pfeffer LM, Slominski AT. CRH inhibits NF-kappaB signaling in human melanocytes. Peptides 2006; 27:3276-83. (Pubitemid 44738166)
37. Slominski AT. On the role of the corticotropinreleasing hormone signaling system in the aetiology of inflammatory skin disorders. Br J Dermatol 2009; 160(2):229-32.
38. Arck PC, Slominski A, Theoharides TC, Peters EM, Paus R. Neuroimmunology of stress: skin takes center stage. J Invest Dermatol 2006; 126(8):1697-704. (Pubitemid 44086503)
39. Slominski AT, Wortsman J. Neuroendocrinology of the skin. Endocr Rev 2000; 21:457-87.
40. Donelan J, Boucher W, Papadopoulou N, Lytinas M, Papaliodis D, Dobner P, Theoharides TC. Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc Natl Acad Sci USA 2006; 103(20):7759-64.
41. Theoharides TC, Kempuraj D, Marchand J, Tzianoumis L, Vasiadi M, Katsarou-Katsari A, Makris M, Kalogeromitros D. Urticaria pigmentosa associated with acute stress and lesional skin mast cell expression of CRF-R1. Clin Exp Dermatol 2009; 34(5):163-6.
42. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 2004; 146(1-2):1-12. (Pubitemid 38032950)
43. Slominski A, Wortsman J, Pisarchik A, Zbytec B, Linton EA, Mazurkiewicz JE, Wei ET. Cutaneous expression of corticotrophin releasing hormone (CRH), urocortin and CRH receptors. FASEB 2001; 15(10):1678-93. (Pubitemid 32730215)
44. Slominski AT, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 2004; 84:1155-228. (Pubitemid 39287950)
45. Slominski AT. Proopiomelanocortin signaling system is operating in mast cells. J Invest Dermatol 2006; 126(9):1934-6.
46. Dessinioti C, Antoniou C, Katsambas A, Stratigos AJ. Melanocortin 1 receptor variants: functional role and pigmentary associations. Photochem Photobiol 2011; 87(5):978-87.
47. Kingo K, Aunin E, Karelson M, Philips MA, Rätsep R, Silm H, Vasar E, Soomets U, Kõks S. Gene expression analysis of melanocortin system in vitiligo. J Dermatol Sci 2007; 48(2): 113-22. (Pubitemid 47380249)
48. Agretti P, De Marco G, Sansone D, et al. Patients affected by vitiligo and autoimmune diseases do not show antibodies interfering with the activity of the melanocortin 1 receptor. J Endocrinol Invest 2010; 33(11):784-8.